Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

(2013) Ilse Krebs et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment

(2012) Kenji Yamashiro et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

One-Year Results of Three Monthly Ranibizumab Injections and As-Needed Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients

(2012) Taiichi Hikichi et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment

(2012) Mads Krüger Falk et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

(2012) Usha Chakravarthy et al.   OPHTHALMOLOGY

Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration

(2012) Gui-shuang Ying et al.   OPHTHALMOLOGY

Combined Intravitreal Ranibizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation

(2011) Masaaki Saito et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION

(2009) MAGDA GHARBIYA et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES